

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

217 **Selected Articles from This Issue**

REVIEWS

219 **Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides**

Jamie V. Shiah, Jennifer R. Grandis, and Daniel E. Johnson

229 **Therapeutic Vulnerabilities of Transcription Factors in AML**

Irum Khan, Elizabeth E. Eklund, and Andrei L. Gartel

SMALL MOLECULE THERAPEUTICS

238 **AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib**

AC Vikki Flemington, Emma J. Davies, David Robinson, Linda C. Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D. Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E. Willis, Martine P. Roudier, Claire Rooney, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Stephen E. Fawell, Clifford D. Jones, Richard A. Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease, and Paul D. Smith

250 **SAR439859, a Novel Selective Estrogen Receptor Degradable (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models**

AC Maysoun Shomali, Jane Cheng, Fangxian Sun, Malvika Koundinya, Zhuyan Guo, Andrew T. Hebert, Jessica McManus, Mikhail N. Levit, Dietmar Hoffmann, Albane Courjaud, Rosalia Arrebola, Hui Cao, Jack Pollard, Joon Sang Lee, Laurent Besret, Anne Caron, Dinesh S. Bangari, Pierre-Yves Abecassis, Laurent Schio, Youssef El-Ahmad, Frank Halley, Michel Tabart, Victor Certal, Fabienne Thompson, Gary McCort, Bruno Filoche-Rommé, Hong Cheng, Carlos Garcia-Echeverria, Laurent Debussche, and Monsif Bouaboula

263 **Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer**

Leslie A. Parsels, Carl G. Engelke, Joshua Parsels, Sheryl A. Flanagan, Qiang Zhang, Daria Tanska, Daniel R. Wahl, Christine E. Canman, Theodore S. Lawrence, and Meredith A. Morgan

274 **Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis**

Rui Jin, Boxuan Liu, Xiuju Liu, Yijian Fan, Wei Peng, Chunzi Huang, Adam Marcus, Gabriel Sica, Melissa Gilbert-Ross, Yuan Liu, and Wei Zhou

284 **Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide**

AC Luping Huang, Denian Wang, Zhongxue Feng, Huan Zhao, Fei Xiao, Yong'gang Wei, Heng Zhang, Hongyu Li, Lingmiao Kong, Min Li, Fei Liu, Haili Zhang, and Wei Zhang

296 **Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis**

Xuemei Xie, Jangsoon Lee, Huey Liu, Troy Pearson, Alexander Y. Lu, Debu Tripathy, Gayathri R. Devi, Chandra Bartholomeusz, and Naoto T. Ueno

307 **Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma**

AC Joshua T. Kowalczyk, Xiaolin Wan, Edjay R. Hernandez, Ruibai Luo, Gaelyn C. Lyons, Kelli M. Wilson, Devorah C. Gallardo, Kristine A. Isanogle, Christina M. Robinson, Arnulfo Mendoza, Christine M. Heske, Jinqi-Qiu Chen, Xiaoling Luo, Alexander E. Kelly, Simone Difilippantino, Robert W. Robey, Craig J. Thomas, Dan L. Sackett, Deborah K. Morrison, Paul A. Randazzo, Lisa M. Miller Jenkins, and Marielle E. Yohe

TABLE OF CONTENTS

LARGE MOLECULE THERAPEUTICS

- 320** **Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models**
Philip N. Moquist, Tim D. Bovee, Andrew B. Waight, Jamie A. Mitchell, Jamie B. Miyamoto, Marsha L. Mason, Kim K. Emmerton, Nicole Stevens, Cindy Balasubramanian, Jessica K. Simmons, Robert P. Lyon, Peter D. Senter, and Svetlana O. Doronina
- 329** **Development of Novel Antibody–Camptothecin Conjugates**
Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter, and Scott C. Jeffrey
- 340** **An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models**
Shang-Fan Yu, Donna W. Lee, Bing Zheng, Geoffrey del Rosario, Douglas Leipold, Helen Booler, Fiona Zhong, Montserrat Carrasco-Triguero, Kyu Hong, Peter Yan, Rebecca K. Rowntree, Melissa M. Schutten, Thomas Pillow, Jack D. Sadowsky, Peter S. Dragovich, and Andrew G. Polson
- 347** **Single-Dose Anti-PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses**
A C Stella A. Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Zhikai Zhang, Sam Feldstein, Radovan Lumban-Tobing, Danielle K. Almstead, Faical Miyara, and Jeegar Patel
- 357** **Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining *In Vitro* Experiments with Systems Modeling**
Arthur J. Van De Vyver, Tina Weinzierl, Miro J. Eigenmann, Nicolas Frances, Sylvia Herter, Regula B. Buser, Jitka Somandin, Sarah Diggelmann, Florian Limani, Thorsten Lehr, Marina Bacac, and Antje-Christine Walz
- 367** **HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells**
Vianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, Anja Baumann, Nicola Giesen, Anikó Pálfi, Christoph Müller, Christian Lutz, Torsten Hechler, Michael Kulke, Carsten Müller-Tidow, Alwin Krämer, Hartmut Goldschmidt, Andreas Pahl, and Marc S. Raab

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 379** **BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma**
Sara Busacca, Laura O'Regan, Anita Singh, Annabel J. Sharkey, Alan G. Dawson, Joanna Dzialo, Aimee Parsons, Neelam Kumar, Laurel M. Schunselaar, Naomi Guppy, Apostolos Nakas, Michael Sheaff, Aaron S. Mansfield, Sam M. Janes, Paul Baas, Andrew M. Fry, and Dean A. Fennell

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 389** **A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma**
Kim A. Reiss, Max M. Wattenberg, Nevena Damjanov, Elizabeth Prechtel Dunphy, Mona Jacobs-Small, M. Judy Lubas, James Robinson, Lisa Diccico, Luis Garcia-Marcano, Michael A. Giannone, Thomas B. Karasic, Emma E. Furth, Erica L. Carpenter, Andrzej P. Wojcieszynski, Robert H. Vonderheide, Gregory L. Beatty, and Edgar Ben-Josef
- 398** **Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells *In Vitro***
Sarah E. Kohrt, Wisam N. Awadallah, Robert A. Phillips III, Thomas C. Case, Renjie Jin, Jagpreet S. Nanda, Xiuping Yu, Peter E. Clark, Yajun Yi, Robert J. Matusik, Philip D. Anderson, and Magdalena M. Grabowska
- 410** **EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1**
Brenna Weadick, Debasis Nayak, Avinash K. Persaud, Sau Wai Hung, Radhika Raj, Moray J. Campbell, Wei Chen, Junan Li, Terence M. Williams, and Rajgopal Govindarajan

MODELS AND TECHNOLOGIES

- 423** **The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils**
Muriel Charlotte Bernhard, Anabel Zwick, Tobias Mohr, Gilles Gasparoni, Oybek Khalmurzaev, Vsevolod Borisovich Matveev, Philine Loertzer, Alexey Pryalukhin, Arndt Hartmann, Carol-Immanuel Geppert, Hagen Loertzer, Heiko Wunderlich, Carsten Maik Naumann, Holger Kalthoff, Kerstin Junker, Sigrun Smola, and Stefan Lohse

TABLE OF CONTENTS

- 438 Cabozantinib Unlocks Efficient *In Vivo* Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors**
Kiranj Kishor Chaudagar, Natalie Landon-Brace, Aniruddh Solanki, Hanna M. Hieromnimon, Emma Hegermiller, Wen Li, Yue Shao, John Joseph, Devan J. Wilkins, Kaela M. Bynoe, Xiang-Ling Li, John G. Clohessy, Soumya Ullas, Jeffrey M. Karp, and Akash Patnaik


CORRECTIONS

- 450 Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis**
Jonathan Cooper, Qingwen Xu, Lu Zhou, Milica Pavlovic, Virginia Ojeda, Kamalika Moulick, Elisa de Stanchina, John T. Poirier, Marjorie Zauderer, Charles M. Rudin, Matthias A. Karajannis, C. Oliver Hanemann, and Filippo G. Giancotti
- 451 Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2**
Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang, and Chuanxin Wang

AC AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Photomicrograph of a normal mesenteric lymph node from a cynomolgus monkey (*Macaca fascicularis*) immunohistochemically stained to identify B-cells with an antibody to CD20 (brown). Depletion of peripheral B-cells and germinal center B-cells of lymphoid tissues was observed in monkeys given an anti-C22 antibody drug conjugate (ADC) containing a novel *seco*-CBI dimer, anti-CD22-thio-Hu anti-CD22-(LC:K149C)-SN36248. These studies provided evidence that this ADC has the potential for a longer duration of response and improved efficacy in indolent non-Hodgkin's lymphoma (NHL) compared to microtubule (MMAE)-containing ADCs and may improve the clinical outcome for patients with this disease. Read the full article, starting on p. 340.



Molecular Cancer Therapeutics

20 (2)

Mol Cancer Ther 2021;20:217-451.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.